IGM Biosciences, Inc.

NasdaqGS:IGMS Stock Report

Market Cap: US$76.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

IGM Biosciences Balance Sheet Health

Financial Health criteria checks 5/6

IGM Biosciences has a total shareholder equity of $100.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $107.0M and $6.1M respectively. IGM Biosciences's EBIT is $10.3M making its interest coverage ratio -1.2. It has cash and short-term investments of $104.3M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-1.2x
CashUS$104.31m
EquityUS$100.93m
Total liabilitiesUS$6.06m
Total assetsUS$106.99m

Recent financial health updates

Analysis Article • Feb 12

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Oct 08

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. Indeed, IGM Biosciences...
Analysis Article • Apr 28

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Nov 20

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 10

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent updates

Analysis Article • Feb 12

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jan 10

IGM Biosciences Stock: Bad News With No Turnaround In Sight

Summary IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a collaboration with Sanofi, IGMS currently has no active pipeline candidates, raising concerns about future prospects. With a 73% workforce reduction and no clear direction, IGM Biosciences appears to be burning cash without any near-term developmental biotech activities. Given the lack of pipeline and high downside risk, I maintain a "Sell" rating on IGMS stock, as there's no compelling reason to invest at this time. Read the full article on Seeking Alpha
Analysis Article • Oct 08

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. Indeed, IGM Biosciences...
Seeking Alpha • Sep 18

IGM Biosciences: Waiting For Godot

Summary Today, we are revisiting with clinical stage biotech concern IGM Biosciences, Inc. for the first time since 2020. IGM Biosciences has a unique approach with IgM antibodies targeting numerous cancer and autoimmune diseases with large potential markets. The company also has a collaboration deal with drug giant Sanofi inked in 2022 and its stock has almost doubled in 2024 year to date. An updated analysis around IGM Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 12

IGM Biosciences: Unlikely To Move The Needle Again In 2024

Summary IGM Biosciences is developing a different class of antibodies to improve on the classic IgG antibodies. Their most advanced project, aplitabart, is being tested in a clinical trial for metastatic colorectal cancer. The company has a decent cash position but faces risks in the high-risk disease area and uncertainty in its collaboration with Sanofi. Read the full article on Seeking Alpha
Analysis Article • Apr 28

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 12

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Summary IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024. The global lupus market is projected to grow to $6.78 billion by 2032 and the global Rheumatoid Arthritis drugs market size is projected to reach $38.61 billion by 2032. Two ongoing studies, one single-arm and one randomized, using Aplitabart for the treatment of patients with 2nd-line metastatic colorectal cancer, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $24.08 billion by 2028. Read the full article on Seeking Alpha
Analysis Article • Nov 20

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 10

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 05

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Sep 23

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 29

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

BofA Securities has initiated IGM Biosciences (NASDAQ:IGMS) with a buy on advantages the company's IgM antibodies in development have over existing antibody therapies. The firm has a $34 price target on shares (~79% upside based on Monday's close). Analyst Geoff Meacham said that IgM antibodies could have better efficacy compared ot the IgG antibodies used in other therapeutics due to additional binding units that can strongly bind to difficult targets. He noted that IGM's (IGMS) lead candidate, imvotamab, has demonstrated positive phase 1 data in B cell non-Hodgkin’s lymphoma. A separate study of the asset in diffuse large B-cell lymphoma and follicular lymphoma. Meacham added that a relationship with Sanofi (SNY) announced in March could earn the IGM (IGMS) more than $6B in milestone payment and also affirms the company's intellectual property. Seeking Alpha's Quant Rating views IGM as a hold with strong grades for growth and momentum.
Seeking Alpha • Aug 08

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

IGM Biosciences press release (NASDAQ:IGMS): Q2 GAAP EPS of -$1.33 misses by $0.93. Revenue of $0.4M. Cash and investments as of June 30, 2022 were $513.2 million, compared to $229.5 million as of December 31, 2021. IGM expects to end 2022 with a balance of approximately $400 million in cash and investments. IGM estimates full year collaboration revenue of approximately $1 million related to the Sanofi agreement. IGM reiterates its previously issued financial guidance expecting full year GAAP operating expenses of $250 million to $260 million including estimated non-cash stock-based compensation expense of approximately $50 million. Shares -1.78%.

Financial Position Analysis

Short Term Liabilities: IGMS's short term assets ($107.0M) exceed its short term liabilities ($6.1M).

Long Term Liabilities: IGMS has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: IGMS is debt free.

Reducing Debt: IGMS had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IGMS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IGMS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.3% each year

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/15 22:50
End of Day Share Price 2025/08/13 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IGM Biosciences, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Biren AminJefferies LLC
Roger SongJefferies LLC